Lyell Immunopharma Acquires ImmPACT Bio to Bolster CAR T-cell Therapy Pipeline

Acquisition Details:
Lyell Immunopharma has entered into a definitive agreement to acquire ImmPACT Bio USA Inc., a privately-owned clinical-stage biotechnology company, for $30 million in cash and 37.5 million shares of Lyell common stock, with additional contingent consideration.

Pipeline Strengthening:
The acquisition strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate for hematologic malignancies, including large B-cell lymphoma.

Clinical Trials:
Data from ImmPACT’s multi-center Phase 1-2 clinical trial of IMPT-314 will be presented at a major medical conference later this year, with a pivotal trial expected to initiate in 2025.

Pipeline Prioritization:
Lyell has prioritized its pipeline to focus on next-generation CAR T-cell therapies, including IMPT-314 and LYL119, and is discontinuing development of LYL797, LYL845, and earlier-stage TIL programs.

Financial Impact:
The acquisition is expected to fund operations into 2027, covering important clinical milestones for each pipeline program.

Strategic Rationale:
The acquisition complements Lyell’s suite of proprietary technologies designed to generate longer-lasting, functional T cells for more durable outcomes in patients with solid tumors and hematologic malignancies.